Illumina Inc said on Wednesday it will divest Grail if the company loses the final appeals in U.S. or European courts.

U.S. genetic testing company Illumina will on Thursday get an order from EU antitrust regulators to sell cancer test maker Grail , a year after the $7.1 billion deal was blocked, a person with dire...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks presents i...

An order from EU competition regulators for Illumina to sell cancer detection test maker Grail could come as early as next week, the Financial Times reported on Monday, citing people with knowledge...

Illumina ( ILMN ), the maker of million-dollar genome sequencing machines that revolutionized the fields of genetics and biotechnology, has fallen hard in the past year. And some analysts believe t...

With the current sector-wide downturn, it's not surprising that several large healthcare stocks are currently undervalued, relative to their intrinsic value, based on their fundamentals, cash flows...

Illumina has had a bad few years due to its troubles with the Grail purchase. It now has new management, and its fines from regulators in the E.U.

Activist investor Icahn's blessing is a relief for the company as it tries to rebound from a bitter proxy fight with the billionaire investor.

Illumina (ILMN) said Tuesday it has chosen Agilent Technologies (A) executive Jacob Thaysen as its new chief executive officer (CEO) as the gene sequencing firm works to recover from a proxy fight ...

Illumina Inc (NASDAQ:ILMN) has a new CEO following its public proxy battle with activist investor Carl Ichan over its troubled acquisition of Grail Inc. The biotech firm named former Agilent execut...

Stocks trend lower this morning entering the first trading of September, a historically weak month for markets. Lowe's (LOW) stock received an upgrade to Outperform from Bernstein analysts.

The announcement comes after a proxy fight with activist investor Carl Icahn, which ended with Illumina's former CEO Francis deSouza voluntarily stepping down.

Illumina Inc. shares ILMN, -0.51% may be poised for a turnaround as the company hunts for a new CEO, Evercore ISI analysts wrote in a research note Friday. The analysts added the stock to their tac...

Illumina (ILMN) boosts genomic capabilities in India with a new state-of-the-art Solutions Center.

Illumina is struggling to get customers to buy its newest products. Wall Street's estimates don't seem to account for that challenge.